

# Parenteral Human Normal Immunoglobuli Adjudication Guideline

**Rule Category:**  
Pharmaceutical

**Ref: No:**  
2022-PH-11

**Version Control:**  
Version No. 5.0

**Effective Date:**  
13/6/2022

**Revision Date:**  
07/10/2025

**Approved by:**  
Daman

**Responsible:**  
Pharmacy Research &  
Governance

**Related Adjudication  
Guidelines:** NA

## Table of Contents

1.	Abstract .....	3
1.1	For Members.....	3
1.2	For Medical Professionals.....	3
2.	Scope .....	3
3.	Adjudication Policy.....	3
3.1	Eligibility / Coverage Criteria.....	3
3.2	Requirements for Coverage .....	4
3.3	Non-Coverage.....	6
3.4	Payment and Coding Rules .....	6
4.	Denial Codes.....	6
5	Appendices .....	7
5.1	References .....	7
5.2	Revision History .....	7

## 1. Abstract

### 1.1 For Members

Immunoglobulin's products are derived from human plasma to treat immune deficiency and related diseases.

Immunodeficiency is caused by an inherent defect in the human immune system, resulting in patients being more susceptible to infection and re-infections.

### 1.2 For Medical Professionals

Human normal Immune globulin Products are sterile products that typically contain more than 95% unmodified IgG and are used for immune deficiency conditions in adults and children.

These products are mainly available in parenteral forms, and once the definitive diagnosis is established, medication is administered either Intravenously or Subcutaneously

## 2. Scope

The scope of this adjudication rule highlights the coverage and medical necessity for intravenous and Subcutaneous Immunoglobulin for the treatment of immunodeficiency and associated conditions for health insurance plans administered by Daman subject to policy terms and conditions.

## 3. Adjudication Policy

### 3.1 Eligibility / Coverage Criteria

#### Parenteral immunoglobulin Eligibility/ Coverage Criteria:

- Daman Covers all types of Parenteral immunoglobulin drugs if medically indicated as per terms and conditions of the health policy administered by Daman.
- All types of Parenteral immunoglobulins drugs are accepted for FDA/EMA label indications.
- The maximum approved dose and frequency should not exceed the ones mentioned in FDA/EMA dose recommendations.

## 3.2 Requirements for Coverage

- Parenteral immunoglobulin drugs request shall go to the Authorization and case management department for proper evaluation.
- All ICD10 codes must be coded to the highest level of specificity.
- IVIG is considered a second-line treatment in systemic sclerosis for patients with skin sclerosis who are refractory to first-line therapies such as Methotrexate (MTX), Mycophenolate mofetil (MMF) or Cyclophosphamide . Refractoriness is defined as no improvement in the Modified Rodnan Skin Score (mRSS) over a period of three to six months.
- Parenteral immunoglobulin only Eligible clinician requests will be considered for evaluation.

Eligible clinician categories
Allergy/Immunology
General Paediatric
Hematology
Oncology
Neurology
Rheumatology
Critical Care/Emergency Medicine
Infectious Disease

## Pharmacology management

Generic Name	Strength	Package Presentation
Human Immunoglobulin	200 mg/ml	5ml, 10ml, 20ml, 40ml
Human Immunoglobulin	165MG/ML	10ml
Human Immunoglobulin	2 g	Vial
Hyaluronidase /Human Immunoglobulin	2.5 g/25ml,200 IU/1.25ml- 5 g/50ml,400 IU/2.5ml- 10 g/100ml,800 IU/5ml- 20 g/200ml,1600 IU/10ml- 30 g/300ml,2400 IU/15ml	25ml, 50ml, 100ml, 200ml, 300ml
Human Immunoglobulin	50 mg/ml	10ml, 20ml, 50ml, 100ml
Human Immunoglobulin	50 mg/ml	100ml
Human Immunoglobulin	100 mg/ml	10ml, 25ml, 50ml, 100ml, 200ml
Human Immunoglobulin	2.5 g	Infusion Vial
Human Immunoglobulin	50 mg/ml	20ml, 50ml, 100ml, 200ml
Human Immunoglobulin	50 mg/ml	50 ml
Human Immunoglobulin	100 mg/ml 50 mg/ml	20ml, 50ml, 100ml, 200ml
Human Immunoglobulin	100 mg/ml	10 ml, 25 ml, 50 ml, 100 ml
Human Immunoglobulin	100 MG/ml 50 mg/ml	20 ml, 50ml, 100ml, 200ml
Human Immunoglobulin	100 MG/ml	25ml, 50ml, 100ml

### 3.3 Non-Coverage

- As per policy terms and conditions for visitor's plan
- Drug codes not listed/tagged as "Abu Dhabi basic drug" are not covered for the basic plan as per the DOH list.
- Parenteral immunoglobulin drug codes prescribed by non-eligible clinician categories will not be covered.

### 3.4 Payment and Coding Rules

- Kindly apply regulator payment rules, and relevant coding manuals for ICD, CPT.
- Maximum duration and treatment are diagnosis-specific, however, maximum loading and maintenance dose of IVIG should always be tailored with label dosage and frequency.
- As per best medical practice, Subcutaneous immunoglobulin (SCIG) home taking, and self-administered drug code need PBM approval.

## 4. Denial Codes

Code	Code Description
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities
MNEC-005	Service/supply may be appropriate, but too frequent
CODE-010	Activity/diagnosis inconsistent with clinician specialty
AUTH-01	Service is not authorized.
NCOV-003	Service(s) is (are) not covered
PRCE-002	Payment is included in the allowance for another service

## 5 Appendices

### 5.1 References

- 1- <https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information#F11513233>
- 2- <https://www.england.nhs.uk/wp-content/uploads/2019/03/PSS9-Immunoglobulin-Commissioning-Guidance-CQUIN-1920.pdf>
- 3- <https://emedicine.medscape.com/article/210367-overview>
- 4- [https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ph\\_5026\\_coveragepositioncriteria\\_Immune\\_Globulin\\_Intravenous\\_IGIV.pdf](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ph_5026_coveragepositioncriteria_Immune_Globulin_Intravenous_IGIV.pdf)
- 5- [http://www.aetna.com/cpb/medical/data/200\\_299/0206.html](http://www.aetna.com/cpb/medical/data/200_299/0206.html)
- 6- <https://ameripharmspecialty.com/immunoglobulins-ig/>
- 7- [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/216671/dh\\_131107.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf)
- 8- <https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Practice%20Management/Practice%20Tools/IVIG-guiding-principles.pdf>
- 9- [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/216671/dh\\_131107.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf)
- 10- [https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-drug-information?search=immunoglobulin&source=panel\\_search\\_result&selectedTitle=1~148&usage\\_type=panel&kp\\_tab=drug\\_general&display\\_rank=1](https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-drug-information?search=immunoglobulin&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1)
- 11- [GAMUNEX-C CIDP Treatment | GAMUNEX®-C \(immune globulin injection\)](#)

### 5.2 Revision History

Date	Version No.	Change(s)
13/5/2022	V1.0	Release of V1.0
16/8/2024	V2.0	AR Review
30/10/2024	V3.0	no changes/ updated in the new AR format
24/07/2025	V4.0	Title updated to Parenteral Human Normal Immunoglobulin to align with scope and terminology.
07/10/2025	V5.0	Adding coverage criteria in systemic sclerosis.

#### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below: The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website. This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.